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Abstract 
Epithelial cell-cell contacts maintain normal glandular tissue homeostasis and their 
breakage can trigger epithelial-to-mesenchymal transition (EMT), a fundamental step in 
the development of metastatic cancer. Despite the ability of C-type lectin domains (CTLDs) 
to modulate cell-cell adhesion it is not known if they modulate epithelial adhesion in EMT 
and tumor progression. Here the multi-CTLD mannose receptor, Endo180 
(MRC2/uPARAP), was shown using Kaplan-Meier analysis to be predictive of survival 
outcome in men with early prostate cancer. A proteomic screen of novel interaction 
partners with the fourth CTLD (CTLD4) in Endo180 revealed that its complex with CD147 
is indispensable for the stability of three-dimensional (3D) acini formed by non-transformed 
prostate epithelial cells (PECs). Mechanistic study using knockdown of Endo180 or 
CD147, and treatment with an Endo180 monoclonal antibody (mAb) targeting CTLD4 
(clone 39.10), or a dominant-negative GST-CTLD4 chimeric protein, induced scattering of 
PECs associated with internalization of Endo180 into endosomes, loss of E-cadherin 
(CDH1/ECAD) and unzipping of cell-cell junctions. These findings are the first to 
demonstrate that a CTLD acts as a suppressor and regulatory switch for EMT; thus, 
positing that stabilization of Endo180-CD147 complex is a viable therapeutic strategy to 
improve rates of prostate cancer survival.  
 
Implications: 
This study identifies the interaction between CTLD4 in Endo180 and CD147 as an EMT 
suppressor and indicates that stabilization of this molecular complex improves prostate 
cancer survival rates. 
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Introduction 
Epithelial-to-mesenchymal transition (EMT) is a reversible trans-differentiation 
program involving a switch from the apical-to-basal polarization of epithelial cells, that are 
adherent to each other and the basement membrane, to a detached mesenchymal-like 
phenotype that is highly motile and invasive (1). EMT is defined according to its different 
biological contexts, including: normal embryonic development (Type I EMT); wound 
healing, tissue regeneration and organ fibrosis (Type II EMT); or tumor progression (Type 
III EMT) (2). EMT has also been closely linked to the early stages of tumor development, 
following the finding that EMT-associated metastatic dissemination precedes detectable 
adenocarcinoma formation in glandular tissue (3). This strongly suggests that molecular 
triggers of EMT in normal epithelial layers should be prioritized as targets for the 
development of therapeutics that can prevent metastasis and improve cancer survival 
rates. 
C-type lectin domains (CTLDs) facilitate the Ca2+-dependent interaction of cell 
surface receptors with carbohydrate moieties, playing critical roles in the innate immune 
response to pathogens, glycoprotein turnover and modulation of cell-matrix and cell-cell 
interactions (4). In a biomarker study we have previously revealed that the multi-CTLD 
receptor Endo180 (CD280, CLEC13E, KIAA0709, MRC2, TEM9, uPARAP) is highly 
expressed in cells with an EMT-like phenotype and correlated with Gleason score in 
prostate cancer (5). In the same study, Endo180 expression was observed in epithelial 
cells lining the ducts of glandular tissue affected by benign prostatic hyperplasia (BPH) or 
low-grade prostate cancer (5). Given that Endo180 expression and subcellular localization 
in constitutively recycling endosomes in mesenchymal-like tumor cells promotes 
extracellular matrix (ECM) remodelling (6-10), disassembly of cell-cell and cell-matrix 
adhesions and cell motility (11, 12), and enhanced tumor growth (7), we hypothesized that 
these pro-EMT properties are negatively regulated in normal prostate epithelial cells 
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(PECs). In accordance, this study has identified a novel EMT-suppressor complex 
between the fourth of eight CTLDs, CTLD4, in Endo180 and the cell adhesion modulator 
CD147 that is indispensible for PEC stability. We suggest that disruption of the 
suppressive Endo180-CD147 complex contributes to the marked decrease in survival 
attributed to Endo180 expression in low-to-intermediate grade (Gleason 5-7 score) 
prostate cancer. Hence, stabilization of the interaction between CTLD4 in Endo180 and 
CD147 is a promising therapeutic strategy that could suppress EMT and metastatic 
dissemination at the early stages of prostate adenocarcinoma formation. 
 
 
Materials and Methods 
Immunohistochemical analysis 
The tissue biopsies on the NCLPC1 and NCLPC4 prostate cancer tissue 
microarrays (TMAs) used in this study were obtained with consent and approved by the 
Research Ethics Committee of Newcastle University Medical School. Both TMAs were 
immunostained with the Endo180 monoclonal antibody (mAb) 39.10 (5, 7, 8) 
(Supplementary Table S1) and a Histostain-Plus detection kit (Invitrogen). Images were 
collected using a Zeiss ChromaVision ACIS II automated slide scanner, an Olympus 
UPlanFLN 10X objective (N.A. = 0.30) and a Sony progressive CCD (charge-coupled 
device) color video camera. Immunohistochemical scores were calculated as % positive 
cells (0 to 100) × staining intensity (0 to 3) with a cut-off score of 30 (range = 0-300) 
distinguishing positive from negative tumors. This immunohistochemical scoring system is 
in routine use in the Departments of Medicine and Surgery & Cancer at Imperial College 
London (13). 
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Cell culture, treatment and morphological analysis 
RWPE-1, PC3, DU145 and B16-F10 obtained from the American Type Culture Collection 
where they were verified by short tandem repeat profiling and phenotypic analysis. BPH-1 
cells were obtained from Dr Simon Hayward (Vanderbilt University Medical Center) under 
a material transfer agreement and verified by phenotypic analysis. Cells were frozen in 
liquid nitrogen and fresh aliquots defrosted and tested for mycoplasma every three months 
(VenorTMGeM Mycoplasma Detection Kit) prior to their experimental use for up to ten 
passages. RWPE-1 cells were grown in complete keratinocyte serum-free media 
(Invitrogen). All other cells were grown in complete RPMI 1640 medium supplemented with 
2 mM L-glutamine, penicillin (50 U/ml) and streptomycin (50 µg/ml) and 10% v/v (PC3, 
DU145 and B16-F10) or 5% v/v (BPH-1) FCS. For 3D acini (RWPE-1 or BPH-1) or 3D 
aggregate (DU145 or PC3) cultures cells were seeded (5 x 103 per well) in 8 well chamber 
slides (Millipore Ltd.) pre-coated with Cultrex® 3D Culture Matrix™ reduced growth factor 
reconstituted basement membrane (rBM) extract (#3445-005-01, Trevigen®) and overlaid 
with growth medium + 2% v/v Cultrex® rBM. Cells were transiently transfected with 
expression vectors or siRNA oligonucleotides (8, 11, 12) (see Supplementary Methods). In 
brief, 24 hours after siRNAs transfection cells were transfected either with Endo180-Flag 
or Flag only expresion vectors and incubated overnight at 37oC with 5% v/v CO2. Cells 
were seeded (5 x 103 per well) onto rBM and remaining cells were lysed for assessment of 
knockdown efficiency using immunoblot analysis. Knockdown was sustained for the 4 day 
duration of the assay. Other treatments included addition of A5/158 or 39.10 mAbs, non-
specific negative control IgG (#ab37355; Abcam), GST, GST-CTLD2 or GST-CTLD4 (see 
Supplementary Methods) to the culture medium with daily replacement. A blinded manual 
scoring approach (two independent scorers) was used to calculate the % of acini 
containing ≥4 cells for each condition relative to the control (set at 100%).  
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Immunoblotting and immunofluorescent staining 
Immunoblotting and immunofluorescent staining of monolayers and 3D cultures 
were carried out with primary antibodies (see Supplementary Table S1); and appropriate 
HRP-conjugated or Alexa®Fluor-conjugated secondary antibodies (8, 11, 12, 14). For 
immunoblots, relative signal intensities for each band was quantified using Image J 
(Version 1.42q), adjusted for loading (GAPDH or ERK-2) and normalized against untreated 
samples (relative levels = 1). For immunofluorescent staining phalloidin-Alexa®Fluor-488 
was added to the secondary antibody dilution to visualize F-actin fibers. TO-PRO®-3 iodide 
or 4’,6-diamidino-2-phenylindole (DAPI) were used as nuclear counterstains. Images were 
acquired using a Axiovert S100 epifluorescent/brightfield microscope with a Zeiss N-
Achroplan 20X objective (N.A. = 0.45), a Hamamatsu Orca AG high-end cooled CCD 
imaging camera and Metamorph® software operating system (Molecular Devices); or a 
Zeiss LSM 510 laser scanning confocal microscope with Zeiss Plan-Apochromat 63X and 
40X oil immersion DIC objectives (N.A. = 1.4), a Hamamatsu CCD imaging camera for 
widefield imaging on an Axioplan 2 mounting and Zeiss LSM 510 Meta operating system. 
Images were equally adjusted for brightness and contrast using Adobe Photoshop CS4 
(Version 11.0.2) or Zeiss LSM Image Browser (Version 4,2,0,121).  
 
Antibody array, pull-down assays and immunoprecipitation 
ARY012 antibody arrays (R&D Systems) were incubated with GST or GST-CTLD4 
elutes following the manufacturer’s protocol. Relative signal intensities of duplicate spots 
(mean ± s.d) were quantified (Image J version 1.42q) and normalized against the internal 
positive control. For pull-down assays GST and GST-fusion proteins conjugated to 
glutathione-sepharose beads were incubated with cell lysates (4ºC, 12 h), washed in GST-
lysis buffer and centrifuged at 14,000 rpm (4ºC, 2 min) (5X), denatured (95°C, 5 min). 
Ectopically expressed Endo-Flag chimeric protein (see Supplementary Methods) was 
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immunoprecipitated from whole cell lysates using a FLAG-tagged protein 
immunoprecipitation kit (#FLAGIPT1; Sigma-Aldrich). Pulled down and immunopreciptated 
proteins were resolved using SDS-PAGE and immunoblotted (see above).  
 
Statistics 
SPSS (Version 19) was used to create Kaplan Meier plots (censored to account for 
any patient withdrawals before the final outcome is observed) and to perform Log Rank, 
Breslow and Tarone-Ware analyses and Student’s t-tests (two tails, α = 0.05).  
 
Results 
Endo180 expression in early prostate neoplasms decreases survival 
Endo180 was analyzed for its contribution to clinical outcome using prostate cancer 
TMAs that were established at the University of Newcastle. In accordance with our earlier 
findings using a commercial TMA (5), high Endo180 expression was observed in the 
epithelium, with lesser staining in the stroma, of non-malignant tumor-adjacent BPH tissue 
cores (Fig. 1A and Supplementary Table S2); and significant increases in Endo180 
expression in PECs in Gleason score 4 and 5 tumor tissue cores compared to non-
malignant tumor-adjacent BPH (Fig. 1B).  
Kaplan-Meier analysis identified Endo180 as an independent predictor of poor 
prognosis, with only 39% (13/33) deaths recorded after five years for Endo180-negative 
tumors compared to 65% (60/93) for Endo180-positive tumors (Fig. 1C and 
Supplementary Table S3 shows deaths [censored] after three, five, seven and ten years, p 
< 0.03). There was a marginal difference in the five year overall survival rate of men with 
low-to-intermediate grade (Gleason sum score 5-7) versus high-grade (Gleason sum score 
8-10) prostate cancer (Fig. 1D and Supplementary Table S3, p > 0.07). For low-to-
intermediate grade tumors there were 21% (3/14) and 67% (16/24) respective deaths 
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recorded in Endo180 negative and positive cases (Fig. 1E and Supplementary Table S3, p 
< 0.02), which despite the relatively low number of patient numbers in this subset, 
indicates that Endo180 expression in these earlier stage neoplasms has a major impact on 
clinical outcome. 
 
Endo180 is necessary for prostate gland acinar stability 
We hypothesized that the significant clinical impact of Endo180 expression at the 
early stages of prostate cancer results from the negative regulation of its pro-invasive 
function being lost. To determine if Endo180 contributes to epithelial stability we 
genetically silenced the receptor during 3D PEC acinar morphogenesis. In accordance, 
the loss of Endo180 induced scattering of RWPE-1 and BPH-1 cells into the surrounding 
rBM (Supplementary Figs. S1A and B), without affecting their cell cycle or viability 
(Supplementary Figs. S2A-C), revealing that a critical biological function of the receptor in 
normal glandular PECs is to stabilize their adherence to each other and the basement 
membrane to help maintain their apical-to-basal polarity. 
Endo180 is an uptake receptor for collagen cleavage products generated by the 
proteolytic activity of membrane type-1 metalloproteinase (MT1-MMP) (15). To test 
whether silencing of MT1-MMP has a similar effect on acinar architecture to Endo180 
knockdown, we depleted MT1-MMP from 3D cultures of RWPE-1 and BPH-1 cells 
(Supplementary Figs. S1A and B). The results confirmed that, unlike Endo180, MT1-MMP 
is not required for the maintenance of PEC acinar homeostasis. In addition, silencing of 
Endo180 in 3D aggregates formed by metastatic prostate tumor cells (PTCs) (PC3 and 
DU145) did not induce scattering into the surrounding rBM (Supplementary Figs. S1A and 
C), which suggests that Endo180-dependent stabilization of cell-cell adhesions is a 
molecular mechanism that is exclusive to non-transformed prostatic epithelia.  
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Endo180 siRNA oligonucleotides #1 and #2 respectively bind to the 3’ UTR non-
coding and mRNA coding regions of the gene (Fig. 2A), therefore oligonucleotide #1 is not 
able to silence ectopically expressed Endo180-Flag (Fig. 2B). We used this distinguishing 
feature of these two oligonucleotides to determine if ectopic expression of Endo180 during 
endogenous receptor silencing can reverse this dramatic change in acinar architecture. 
Indeed, ectopic Endo180-Flag expression in PECs rescued the effect of Endo180 siRNA 
oligonucleotide #1, but not #2, on acinar cell-cell stability (untreated control = 100% fully 
formed acini; control siRNA = 88.0 ± 18.7%; oligonucleotide #1 = 88.7 ± 24.9%; 
oligonucleotide #2 = 29.6 ± 5.5%) (Figs. 2C and D). As expected, ectopic expression of 
Flag alone did not rescue the inhibitory effect of either Endo180 siRNA oligonucleotide 
(untreated control = 100%; control siRNA = 97.7 ± 25.8%; oligonucleotide #1 = 24.1 ± 
1.3%; oligonucleotide #2 = 23.2 ± 6.2%) (Figs. 2C and D). Acinar morphogenesis by 
RWPE-1-Flag and RWPE-1-Endo180-Flag cells treated with Endo180 siRNA 
oligonucleotide #1 was significantly different (Student test: p = 0.01, two tails) (Fig. 2D). 
Moreover, Endo180-Flag was clearly localized to the basolateral membrane of PECs 
treated with Endo180 siRNA oligonucleotide #1 (Fig. 2C). This data establishes that loss of 
Endo180 from the plasma membrane in epithelial cell monolayers may be a driving force 
behind the switch to an EMT-like phenotype and the dissemination of cells into the 
surrounding matrix. 
 
CTLD4 in Endo180 receptor modulates glandular epithelial cell-cell adhesion 
Differential staining patterns for Endo180 with different mAbs indicated that two 
subcellular pools of the receptor are present in PEC acini. The first subcellular pool of 
Endo180 is localized at the basolateral membrane and recognized by A5/158 mAb; 
whereas the second is localized in endosomes and recognized by 39.10 mAb (Fig. 3A). 
Treatment with the two antibodies revealed that incubation with 39.10 mAb, but not 
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A5/158, resulted in the same effect as Endo180 silencing by scattering PECs into the 
surrounding rBM (Fig. 3B). Epitope mapping has confirmed that A5/158 mAb binds to 
CTLD2 in Endo180 (11). Using a similar epitope mapping approach that involved 
immunoblot analysis of truncated forms of Endo180 with successive deletions in each of 
its domains down to CTLD5, it was confirmed that 39.10 mAb binds to CTLD4 
(Supplementary Figs. S3A and B).  This indicates that CTLD4, but not CTLD2, is required 
for PEC adhesion. The inability of 39.10 mAb to promote cell scattering from 3D 
aggregates formed by metastatic PTCs (Supplementary Fig. S4) is likely to be the result of 
constitutive recycling of the receptor from the plasma membrane and its localization to 
endosomes in transformed mesenchymal-like cells (Fig. 3C) (11, 12). 
The strong localization of Endo180 observed at the basolateral membrane of 
untreated or mouse IgG treated PEC monolayers was lost following treatment with 39.10 
mAb, but not A5/158 mAb, resulting in most of the receptor being localized to endosomes 
(Fig. 3C). In line with the induction of programmed EMT, the treatment of PECs with 39.10 
mAb resulted in a decrease in total cellular levels of E-cadherin (0.3-fold) and β-catenin 
(0.7-fold) (Fig. 3D). In contrast, levels of these core cell-cell adhesion components were 
unaffected by treatment with A5/158 mAb (E-cadherin: 0.9-fold; β-catenin: 0.9-fold) or IgG 
control (E-cadherin: 0.8-fold; β-catenin: 1.0-fold) (Fig. 3D). Again the disseminated PECs 
retained their ability to survive, as confirmed by the lack of effect of 39.10 mAb on their cell 
cycle and viability (Supplementary Figs. S2D-G). 
We next considered the hypothesis that the inability of 39.10 mAb to recognize 
Endo180 localized at the plasma membrane is due to CTLD4 epitope being masked by 
unknown interaction partner(s). We also predicted that treatment with soluble GST-CTLD4 
would disrupt epithelial cell-cell contacts by imposing a dominant negative effect on the 
unknown interaction partner(s) (Fig. 4A). To test this hypothesis we generated GST-
CTLD2 and GST-CTLD4 chimeric proteins (Fig. 4B) and used them as competing agents 
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for CTLD2 and CTLD4 ligands during PEC acinar morphogenesis. In agreement with 
antibody blocking experiments, GST-CTLD4, but not GST-CTLD2, induced scattering of 
RWPE-1 and BPH-1 cells into the surrounding rBM (Fig. 4C) without affecting cell viability 
(Supplementary Figs. S2H).  
 
CTLD4 in Endo180 receptor interacts with highly glycosylated CD147 
Proteomic analysis of interaction partners eluted from GST-CTLD4-conjugated 
sepharose beads that had been incubated with PEC whole cell lysates revealed that 
Endo180 forms a molecular complex with CD147 and CD36 (Fig. 4D and E). Given that 
CD147 is associated with prostate cancer progression (16) we decided to explore its 
cooperative role with Endo180. Endo180-CTLD4 and CD147 complex formation was 
further demonstrated by the ability of GST-CTLD4, but not GST-CTLD2 or GST alone, to 
bind to the highly glycosylated and active form of CD147 (Supplementary Fig. S5A). Anti-
Flag immunoprecipitation of highly glycosylated CD147 from PECs transfected with 
Endo180-Flag also consolidated its interaction with Endo180 (Supplementary Fig. S5B). 
Conversely, E-cadherin, β-catenin and ZO-1 were not detected in Endo180-Flag 
immunoprecipitates (Supplementary Fig. S5C), suggesting that Endo180 is not 
incorporated into adherens and tight junction protein complexes. This is not surprising 
given that Endo180 is weakly localized in lateral cell-cell junctions and strongly localized at 
the basal plasma membrane of PEC acini (Fig. 3A). In agreement, E-cadherin and β-
catenin were not identified as Endo180 interaction partners (Supplementary Fig. S5C). 
 
Endo180-CD147 complex disassembly promotes EMT 
Glycosylation of CD147, following its disassociation from caveolin-1, promotes its 
self-aggregation, stabilization at the plasma membrane and enhanced cell adhesion (17). 
Based on the ability of highly glycosylated CD147 localized at the plasma membrane to 
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promote cell adhesion, we determined whether its interaction with CTLD4 in Endo180 was 
responsible for cell-cell adhesion stability in PEC acini. Incubation of PECs with increasing 
concentrations of the dominant negative GST-CTLD4 construct decreased the ratio of 
high/low glycosylated CD147 present in whole cell lysates (2 µg/ml: ratio = 0.71; 4 µg/ml: 
ratio = 0.25) compared to untreated cells (ratio = 1.0) or cells treated with GST alone (ratio 
= 1.16) as determined by semi-quantitative immunoblot analysis (Fig. 5A). The same 
treatment did not induce any change in the glycosylation status of CD147 in PTC’s (Fig. 
5A). Similar to treatment with GST-CTLD4, treatment with 39.10 mAb also decreased the 
ratio of high/low glycosylated CD147 in PECs (control IgG treatment: ratio = 1.85; 39.10 
mAb treatment: ratio = 0.16) but not PTCs (Fig. 5B). The shift in the glycosylation status of 
CD147 - from high to low - induced by GST-CTLD4 in PECs correlated CD147 
internalization (Fig. 5C, arrowheads) and unzipping of adherens junctions (Fig. 5C, 
arrows). These results consolidate the link between Endo180-CD147 complex disruption 
and the initiation of EMT in prostate epithelial monolayers.  
To shed more light on our newly established model of Endo180-CD147 dependent 
cell-cell adhesion and EMT suppression we costained PEC acini with anti-CD147 and 
A5/158 or 39.10 mAbs. The findings revealed that CD147 localizes with Endo180 at the 
basal plasma membrane but not in endosomes (Fig. 6A). Finally, we demonstrated that 
CD147 silencing (Fig. 6B) also scattered PECs into their surrounding rBM (Fig. 6C), which 
is in agreement with the pro-EMT effect observed following their treatment with Endo180 
siRNA oligonucleotides (Supplementary Fig. S1B) 39.10 mAb (Fig. 3B) and GST-CTLD4 
(Fig. 4C). 
 
Discussion  
The revelation that Endo180 interacts with, and stabilizes, highly glycosylated 
CD147 at the plasma membrane of normal PECs, and that destabilization of the complex 
Rodriguez-Teja et al.    C-type lectin domain acts as tumor suppressor 
 
    13 
leads to Type III EMT, establishes a new type of molecular trigger for the development of 
invasive prostate cancer. The findings of this study also confirm that, similar to the 
upregulation of CD147 (5, 16), the increased expression of Endo180 is correlated with 
increasing Gleason score (Fig. 1B) and has prognostic value as an independent predictor 
of overall survival (Fig. 1C). Surprisingly, Kaplan Meier analysis revealed that Endo180 is 
a stronger predictor of survival than Gleason score. However, the cut-off between Gleason 
5-7 and Gleason 8-10 used may have skewed the latter outcome given that ≤	Gleason 7 
(3+4) and ≥ Gleason 7 (4+3) scores confer differences in overall survival (18). Future 
studies using larger patient cohorts are needed to determine if Endo180 expression can 
differentially affect the survival of men with low (≤	Gleason 6) and intermediate (Gleason 7 
(3+4)) risk tumors.  
Although previous work has suggested that there is a close association between 
Endo180 expression and an EMT-like phenotype in transformed cells derived from breast 
(7), pancreatic (10) and prostate (5) cancer the divergent mechanistic roles of Endo180 in 
this fundamental process had not been appreciated. Endo180 and CD147 have both been 
correlated with low levels of E-cadherin in tumor tissue and both are under the 
transcriptional regulation of the core EMT trigger transforming growth factor-beta (TGF-β) 
(7, 8, 19, 20). In an aligned study we have demonstrated that the stiff microenvironment 
associated with advanced glycation endproduct accumulation and collagen crosslinking of 
the basement membrane in the prostate gland is sufficient to activate an EMT-like 
phenotype in PEC acini by forcing the relocalization of Endo180 into endosomes and 
initiating an Endo180-dependent contractile signaling cascade that promotes cell invasion 
(Rodriguez-Teja et al., unpublished data). Indeed, extracellular matrix stiffness has been 
identified as a regulator that can release matricellular TGF-β in a number of pathologies 
(21). Considering the findings reported here, we believe that the TGF-β-Endo180 axis is a 
central regulatory pathway that controls the induction of EMT in human glandular tissue. It 
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is possible that the EMT suppressor function of membrane bound Endo180 in non-
oncogenic epithelia, and the pro-metastatic function of Endo180 in endosomes in newly 
established tumors, underpins the paradoxical roles of TGF-β as a suppressor and 
promoter of cancer progression (22). Our future investigations will be focused on 
unraveling the complex environmental factors and mechanisms - including tissue hypoxia, 
age-dependent ECM stiffness and obesity-associated inflammation – that lie upstream of 
Endo180-CD147 complex disruption and can drive the progression of indolent lesions to 
aggressive neoplasms in prostate and other glandular epithelia. It will also be important to 
establish which other specific EMT-associated events, in addition to the downregulation of 
E-cadherin, are triggered by Endo180-CD147 complex disruption. This analysis could 
include evaluation of master regulators of EMT, including Snail, Slug, Twist, Zeb, and 
microRNAs (23). 
The characterization of Endo180 for its carbohydrate binding capacity has so far 
only included an in vitro analysis that identified CTLD2 as the sole CTLD possessing lectin 
activity (24). The finding here that CTLD4 in Endo180 binds to highly glycosylated CD147 
in 3D acini culture suggests that also it behaves as an active lectin in an in vivo context. 
Interestingly, in vitro analysis and in vivo evidence has confirmed that lectin activity also 
resides in the fourth CTLD of the related mannose receptor (25), which points towards an 
evolutionary basis for the position of this domain in multi-CTLD receptors. Interestingly, 
two other cell surface receptors that each have a single CTLD and confined to the tumor 
vasculature are being considered as molecular targets of anti-angiogenics for indirect 
treatment of solid tumors. The first, CLEC14A (EGFR-5), is exclusively expressed by 
vascular endothelial cells and promotes cell-cell adhesion and neo-angiogenesis via its 
single CTLD (26-28). The second, endosialin (CD248, TEM-1), is expressed by stromal 
fibroblasts and pericytes and can promote tumor angiogenesis and growth (29, 30). Our 
study now opens the way for CTLD4 in Endo180 to be characterized for its cooperative 
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role with CD36 (see Fig. 4D) and other glycosylated ligands and bona fide lectin activity in 
addition to its exploitation as a therapeutic target in metastatic cancer. 
The importance of CTLD4 for the formation of the suppressive Endo180-CD147 
complex in PECs was not uncovered in Endo180ΔEx2-6/ΔEx2-6 mice that express a truncated 
form of the Endo180 receptor, including an intact CTLD4, and reach adulthood (31, 32). 
Nevertheless, our analysis of prostate tissue from adult Endo180ΔEx2-6/ΔEx2-6 mice has 
revealed that a significant architectural change occurs that closely recapitulates prostatic 
intraepithelial neoplasia (PIN), a common precursor for invasive prostate cancer 
(Rodriguez-Teja et al., unpublished data). This finding can be explained by experimental 
evidence that suggests constitutively exposed CTLD2 in Endo180ΔEx2-6/ΔEx2-6 mice binds to 
glycated collagen (33) to promote mechanotransduction and cell invasion (Rodriguez-Teja 
et al., unpublished data). Given that only 3.5% of CD147-/- mice reach adulthood due to 
failed blastocyst implantation (34) it will be of considerable interest to determine if targeted 
deletion of CTLD4 or full genetic ablation of Endo180 results in a developmental defect. 
The impact of Endo180 silencing and Endo180-CD147 complex disruption in different 
glandular epithelia also needs exploration using appropriate in vivo models. 
Together with previous findings this study establishes a new mechanism for the 
early stages of tumor formation that involves: (a) Endo180-CTLD4 and CD147 complex 
disruption; (b) Endo180 internalization into the cytoplasm via clathrin-dependent 
endocytosis (c) CD147 internalization into the cytoplasm via a clathrin-independent 
mechanism (35); and (d) generation of spatiotemporal contractile signals (RhoA-ROCK-
MLC2) from Endo180-containing endosomes that destabilize cell-cell adhesions, increase 
the turnover of cell-matrix adhesions and endows disseminated cells with the capacity to 
migrate via ligand-specific chemotactic mechanisms towards distant sites (11, 12) (Fig. 7). 
It is also plausible that CD147 and endosomal Endo180 help to coordinate ECM turnover 
via their respective activation of MMPs (36) and participation in collagen remodeling (7, 8, 
Rodriguez-Teja et al.    C-type lectin domain acts as tumor suppressor 
 
    16 
14, 33). In addition to inducing Endo180 internalization, Endo180-CTLD4 and CD147 
complex disruption deglycosylates and internalizes CD147. Hence, it is possible that 
Endo180 stabilizes CD147 at the plasma membrane by competing with its negative 
regulator caveolin-1 (17).  
Progression towards metastatic castrate resistant prostate cancer and the 
contribution of aberrant androgen signaling to this process remains a major therapeutic 
challenge (37). Negative androgen receptor (AR) status is correlated with the expression 
of Endo180 in breast cancer (7). This suggests that dysregulation of the androgen axis 
and AR signaling may act as a trigger for Endo180 expression and enhanced metastatic 
potential. A putative role for Endo180 in androgen-independent prostate cancer is further 
consolidated by its absence from the androgen-dependent and non-invasive LNCaP 
prostate cancer cell line (8). Together these observations set a precedent for investigating 
the interaction between AR signaling and the Endo180 axis.  
In combination with the continued validation of soluble Endo180 in serum as a 
highly sensitive and specific biomarker for metastatic disease (38); the findings of this 
study suggest that strategies for anti-metastatic therapy should: (a) promote stabilization of 
the suppressive complex between CTLD4 in Endo180 and CD147 at the plasma 
membrane, in the case of indolent diseases like BPH; and (b) exclusively target 
endosomal Endo180, in the case of aggressive tumors. We predict that the aligned 
introduction of Endo180 as a prognostic marker and therapeutic target will have a 
significant impact on the prognosis and prevention of metastasis in prostate cancer and 
could also be of benefit in the management of other types of carcinoma. 
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Figure Legends 
Figure 1. Endo180 predicts overall survival. A, Endo180 immunostaining in non-malignant 
and malignant prostate tissue; magnification, x10; scale bar, 200 µm. B, Box and whiskers 
plot shows Endo180 correlation with Gleason score; total range, interquartile distribution, 
outliers (open circles) and median value (horizontal line) of Endo180 scores for NCLPC4 
TMA: non-malignant tumor-adjacent tissue (n = 35); Gleason score 3 (n = 36), 4 (n = 58) 
and 5 (n = 48). Kaplan-Meier five-year survival analysis of NCLPC1/4 TMAs (n = 157) for: 
C, Endo180 negative (black line) and positive (gray line) tumors; D, Gleason score 5-7 
(black line) and 8-10 (gray line) tumors; and E, Endo180 negative (black line) and positive 
(gray line) tumors in the Gleason 5-7 subset; p-values shown for Log Rank, Breslow and 
Tarone-Ware tests. 
 
Figure 2. Membrane localized Endo180 is indispensable for cell-cell adhesion. A, 
Schematic of experimental timeline and annealing sites for Endo180 siRNA 
oligonucleotides #1 and #2. B, Immunoblots show Endo180-Flag, endogenous Endo180 
and GAPDH levels in RWPE-1 cells expressing Flag or Endo180-Flag that had been 
untreated or treated with control siRNA or Endo180 siRNA oligonucleotides #1 and #2; 
MW markers, kDa. C, RWPE-1 cells cultured for three days in rBM stained with DAPI 
(blue) and anti-Flag to detect Endo180-Flag (green); magnification, x20; scale bar, 20 µm. 
D, Average ± s.d. % of fully formed acini by cells expressing Endo180-Flag (gray bars) or 
empty vector (black bars); untreated cells = 100%; *significant difference, p = 0.01. 
 
Figure 3. CTLD4 in Endo180 is required for cell-cell adhesion. A, Epitopes in human 
Endo180 ectodomain recognized by A5/158 and 39.10 mAbs and corresponding 
immunostaining in RWPE-1 acini (inset); magnification x63; scale bar, 10 µm. B, RWPE-1 
cells cultured in rBM without (untreated) or with mouse IgG, A5/158 and 39.10 for six or 
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twelve days stained with phalloidin (green) and TO-PRO-3® (blue); magnification x40; 
scale bar, 20 µm. C, RWPE-1 and PC3 cell monolayers cultured without (untreated) or 
with mouse IgG, A5/158 or 39.10 for six days stained with A5/158 (green) and DAPI 
(blue); magnification x63; scale bar, 20 µm. D, Immunoblots show E-cadherin, β-catenin 
and ERK2 levels in RWPE-1 cells untreated or treated with IgG control or A5/158 and 
39.10; MW markers, kDa. Graph shows relative levels of E-cadherin (black bars) and β-
catenin (gray bars) adjusted against ERK2 levels and normalized against untreated cells 
(relative levels = 1). 
 
Figure 4. CTLD4-dependent cell-cell adhesion is associated with its novel interaction 
partner CD147. A, Epitopes in human Endo180 ectodomain recognized by A5/158 and 
39.10 mAbs and corresponding GST-CTLD2 and GST-CTLD4 chimeric proteins 
generated. B, Coomassie stain of elutes containing purified GST, GST-CTLD2, GST-
CTLD4 and BSA; MW markers, kDa. C, RWPE-1 and BPH-1 cells cultured in rBM without 
(untreated) or with purified GST, GST-CTLD2 or GST-CTLD4 (4 µg/ml a day for four days) 
stained with DAPI; magnification, x20; scale bar, 50 µm. D, GST-CTLD4 and GST whole 
cell lysate pull-downs analyzed using an array containing fifty-seven antibodies printed in 
duplicate. Proteins of interest eluted (black arrows) include: CD36/SR-B3 (Entrez gene 
#948), CD18/integrin β2 (Entrez gene #3689), IL-1RII (Entrez gene #7850) and 
CD147/EMMPRIN (Entrez gene #682). E, Average relative density ± s.d. (pixels/unit area) 
of duplicate spots (GST, black bars; GST-CTLD4, gray bars) normalized against internal 
positive control (+ Cntrl, panel D). 
 
Figure 5. Endo180-CD147 complex disruption decreases glycosylation and promotes 
internalization of CD147 with unzipping of cell-cell junctions. Immunoblots of CD147 
(high/low glycosylated forms indicated) and GAPDH levels in RWPE-1 and PC3 whole cell 
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lysates following treatment with GST or GST-CTLD4 (A) and mouse IgG or 39.10 mAb 
(B); MW markers, kDa. Graph shows relative amount of CD147 with high (above 43 kDa, 
black bars) and low (below 43 kDa, gray bars) glycosylation compared to untreated cells 
adjusted against GAPDH. C, Immunostaining of CD147 (green), E-cadherin (red) and TO-
PRO-3® (blue) in RWPE-1 monolayers; arrowheads, cells with internalized CD147; 
arrows, unzipped cell-cell junctions; magnification, x63; scale bar, 10 µm. 
 
Figure 6. CD147 colocalizes with Endo180 at the basolateral membrane and is required 
for cell-cell adhesion. A, Endo180 (green, A5/158 mAb [IgG1] and 39.10 mAb [IgG1]), 
CD147 (red, anti-human CD147 mAb [IgG2aκ]) and TO-PRO-3® (blue) immunostaining of 
RWPE-1 cells cultured for six days in rBM; magnification, x63; scale bar, 10 µm. B, 
Immunoblots show endogenous CD147 and GAPDH levels in RWPE-1 cells treated with 
control or CD147 (#1 and #2) siRNA oligonucleotides; MW markers, kDa. Graph shows 
CD147 levels adjusted against GAPDH and normalized against untreated control (relative 
levels = 1). C, Cells seeded on rBM for three days stained with DAPI; magnification, x20; 
scale bar, 50 µm.  
 
Figure 7. Schematic showing how Endo180-CTLD4 and CD147 complex stabilizes normal 
epithelial apical-to-basal cell polarity. Endo180-CTLD4 and CD147 complex disruption 
results in Endo180 internalization via clathrin-dependent endocytosis and CD147 
internalization via a clathrin-independent mechanism (35). Endo180-containing 
endosomes generate spatiotemporal contractile signals that destabilize cell-cell 
adhesions, increase cell-matrix adhesion turnover and endow disseminated cells with pro-
migratory and chemotactic properties (12). CD147 and Endo180 remodel the extracellular 
matrix via respective activation of MMPs (36) and participation in collagen remodeling (7, 
8, 14, 31, 33) via their distinct cellular pathways. 
